Purposeful search of anticancer agents among [1,2,4]triazino[2,3-c] quinazolines derivatives as one of the directions in realization the import substitution strategy of chemotherapy medicines
DOI:
https://doi.org/10.24959/uekj.18.19Keywords:
antineoplastic drugs, import substitution, planning, researchAbstract
Import-substitution of medicines, in particular antitumor activity, is an important component of the strategy for medical industry development, and among other, provides for the scientific research activation aimed at the creation of innovative medicines.
Aim. The presented work is a generalization of own experience in planning and realization of projects on creation of synthetic compounds with significant anticancer activity based on [1,2,4]triazino[2,3- c]quinazoline derivatives and products of their structural modification.
Results. We conducted work planning, which allowed us to identify the following stages of the study: the choice of the research direction, the choice of the class of compounds as objects of pharmacological research, the choice of approaches to the design of potential bioactive molecules, the biological activity pre-screening, the primary screening for anticancer activity of synthesized compounds, analysis of obtained data, profound study of the anticancer activity. The search of novel anticancer agents was conducted among the series of [1,2,4]triazino[2,3-c]quinazolines and related compounds, that may be obtained by modification of substituted 3-(2-aminophenyl)-6-R-1,2,4-triazino-5(2H)- ones. Considering to the structure similarity of studied compounds to the well-known anticancer drugs – 4-anilinoquinazolines, they may reveal tyrosine-kinase inhibiting effects and as result anticancer activity. The biological activity pre-screening using molecular docking study and bioluminescence inhibition model, in vitro study of FGFR1-inhibiting activity and in vitro study of anticancer activity were conducted for synthesized compounds. As a result of the project, lead-compounds were obtained, as well, as additional information for further studies.
Conclusions. One of the possible variants for the research conduction aimed at creating of innovative anticancer drugs has been developed. The presented strategy can be used by small groups of researchers in universities, research institutions and commercial pharmaceutical enterprises.
References
Kotvitska, A. A., &Kostiuk, V. H. (2016). Research of normative legal regulation of import substitution production of medicines in Ukraine. Upravlìnnâ, ekonomìka ta zabezpečennâ âkostì v farmacìï, 1(45), 44–48.
https://doi.org/10.24959/uekj.16.6
Demchenko, N. V. (2014). Visnyk ONU im. I. I. Mechnykova, 19 (2/2), 56–60.
Campbell, I. B., Macdonald, S. J. F., Procopiou, P. A. (2018). Medicinal chemistry in drug discovery in big pharma: past, present and future. Drug Discovery Today, 23(2), 216.https://doi.org/10.1016/j.drudis.2017.10.007
Slobodyanyuk, M., Samborskyi, O., &Hermanowski, T. (2017). Methodical approach to economic indicators forecasting in new medicines development. Upravlìnnâ, ekonomìka ta zabezpečennâ âkostì v farmacìï,
(52), 50–58.https://doi.org/10.24959/uekj.17.32
Cohen, P. (2002). Proteinkinases — themaj or drug targets of the twenty-first century. Nature Reviews Drug Discovery, 1, 309.
Levitzki, A., Gazit, A. (1995).Tyrosine Kinase Inhibition: An Approachto Drug Development. Science, 267(5205), 1782.
Smaill, J. B., Showalter, H. D. H., Zhou, H., Bridges, A. J., McNamara, D. J., Fry, D. W., … Denny, W. A. (2001). Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d] pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 44(3), 429–440. https://doi.org/10.1021/jm000372i
Tsou, H.-R., Mamuya, N., Johnson, B. D., Reich, M. F., Gruber, B. C., Ye, F., …Wissner, A. (2001). 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity. Journal of Medicinal Chemistry, 44(17), 2719–2734. https://doi.org/10.1021/jm0005555
Voskoboynik, A. Y., Scorina, D. Y., Sergeieva, T. Y., Kovalenko, S. I., Okovytyy, S. I., Omelchenko, I. V., & Shishkin, O. V. (2015). Interaction of 3-(2-Aminophenyl)-6-R1-1,2,4-triazin-5-ones with Acylating Reagents:
An Efficient Method for Preparation of 6-Substituted 3-R1-2H [1,2,4]triazino[2,3-c]quinazolin2-ones. Journal of Heterocyclic Chemistry, 53(3), 776–783. https://doi.org/10.1002/jhet.2120
Voskoboynik, O. Y., Кovalenko, S. I., Okovytyy, S. I., &Shishkina, S. V. (2017). Dimethyl Acetylenedicarboxylate in Reactions with Substituted 3-(2-aminophenyl)-6-R1-1,2,4-triazin-5-(2H)-ones: Structure and
Properties of the Products. Journal of Heterocyclic Chemistry, 54(3), 2038–2042. https://doi.org/10.1002/jhet.2801
Berest, G. G., Voskoboynik, O. Y., Kovalenko, S. I., Antypenko, O. M., Nosulenko, I. S., Katsev, A. M., & Shandrovskaya, O. S. (2011). Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides. European Journal of Medicinal Chemistry, 46(12), 6066–6074. https://doi.org/10.1016/j.ejmech.2011.10.022
Sergeieva, T. Y., Voskoboynik, O. Y., Okovytyy, S. I., Kovalenko, S. I., Shishkina, S. V., Shishkin, O. V., & Leszczynski, J. (2014). Hydrazinolysis of 3-R-[1,2,4]Triazino[2,3-c]quinazolin-2-ones. Synthetic and Theoretical Aspects. The Journal of PhysicalChemistry A, 118(10), 1895–1905. https://doi.org/10.1021/jp4052616
Hastie, C. J., McLauchlan, H. J., & Cohen, P. (2006). Assay of protein kinases using radiolabeled ATP: a protocol. Nature Protocols, 1(2), 968-971. https://doi.org/10.1038/nprot.2006.149
Katsev, A. M. (2002). Utilities of Lumino us Bacteria from the Black Sea. Applied Biochemistry and Microbiology, 38 (2), 189.
Holbeck, S. (2004). Update on NCI in vitro drug screen utilities. European Journal of Cancer, 40(6), 785–793. https://doi.org/10.1016/j.ejca.2003.11.022
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
